Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the Department of Paediatrics, and Ashall Professor of Infection and Immunity has today been elected a Fellow of the Royal Society.

Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group, has been elected a Fellow of the Royal Society

This accolade is one of the highest honours in science and is given to individuals who have made a "substantial contribution to the improvement of natural knowledge, including mathematics, engineering science and medical science". The award recognises his unique contributions to understanding human immunity, his ground-breaking research on vaccines to prevent life-threatening childhood diseases like typhoid, meningitis and pneumonia, and his invaluable leadership in the development of vaccines for outbreaks of influenza, Ebola, and COVID-19 among others.

Professor Sir Andrew Pollard said: "It is a huge honour to be elected as a Fellow of the Royal Society to join these most distinguished scientists of our time, standing on the shoulders of those past Fellows who changed our world over the past three and a half centuries.  I am more than aware that this is not about me but recognition of the large team of brilliant researchers at the Oxford Vaccine Group and our global collaborators who have made extraordinary contributions to improving lives through immunisation ."

The Royal Society, established over 360 years ago, is the world's oldest scientific academy in continuous existence, dedicated to promoting excellence in science.  

Similar stories

New clinical trials begin in Burkina Faso

Vaccinations have started at the Institut de Recherche en Sciences de la Santé – Clinical Research Unit of Nanoro (IRSS-URCN), Burkina Faso for two clinical trials to assess the blood-stage malaria vaccine candidates R78C and RH5.1 with Matrix-M (developed by the Draper Lab in the Department of Paediatrics), in combination with the R21/​Matrix-M vaccine, which targets the earlier liver-stage. The trials are sponsored by the University of Oxford (UOXF), UK, with the European Vaccine Initiative (EVI) acting as both a co-funder and collaborator. These exciting studies are expected to provide proof-of-concept for the use of a multi-stage vaccine to extend the protection against malaria and help lead to future efforts to eliminate it by targeting two stages of the parasite’s life-cycle.